ACE2 and COVID-19: This pathogenic effect appears to be mediated by the decrease in uPAR expression in the specific lung cells of COVID-19 patients, which may lead to pro-fibrogenic accumulation of inactive uPA followed by IL-6 and ACE2 upregulation and EMT induction (Figure 10).